



CLAIMS:

1. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 21), or a salt thereof.

2. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 22), or a salt thereof.

3. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 21), or a salt thereof.


4. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 22), or a salt thereof.


5. The modified oligonucleotide of any of claims 1-4, which is the sodium salt or the potassium salt.

6. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 21).

7. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 22).

8. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 21).

9. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 22).

10. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation:

${}^m\text{C}_{\text{ns}} \text{A}_{\text{no}} {}^m\text{C}_{\text{ns}} \text{T}_{\text{no}} \text{T}_{\text{ns}} \text{T}_{\text{ns}} {}^m\text{C}_{\text{ns}} \text{A}_{\text{ns}} \text{T}_{\text{ns}} \text{A}_{\text{ns}} \text{A}_{\text{ns}} \text{T}_{\text{ns}} \text{G}_{\text{ns}} {}^m\text{C}_{\text{ns}} \text{T}_{\text{ns}} \text{G}_{\text{ns}} \text{G}_{\text{ns}} {}^m\text{C}_{\text{n}}$ (SEQ ID NO: 21), wherein:

A = an adenine nucleobase,

${}^m\text{C}$ = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

n = a 2'-NMA sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

11. An oligomeric compound comprising a modified oligonucleotide according to the following chemical

notation: $\text{T}_{\text{co}} \text{T}_{\text{ns}} {}^m\text{C}_{\text{ns}} \text{A}_{\text{ns}} {}^m\text{C}_{\text{ns}} \text{T}_{\text{ns}} \text{T}_{\text{ns}} \text{T}_{\text{ns}} {}^m\text{C}_{\text{ns}} \text{A}_{\text{ns}} \text{T}_{\text{ns}} \text{A}_{\text{ns}} \text{A}_{\text{ns}} \text{T}_{\text{ns}} \text{G}_{\text{ns}} {}^m\text{C}_{\text{ns}} \text{T}_{\text{ns}} \text{G}_{\text{ns}} \text{G}_{\text{no}} {}^m\text{C}_{\text{c}}$ (SEQ ID NO: 22), wherein:

A = an adenine nucleobase,
^mC = a 5-methylcytosine nucleobase,
 G = a guanine nucleobase,
 T = a thymine nucleobase,
 e = a 2'-MOE sugar moiety,
 n = a 2'-NMA sugar moiety,
 s = a phosphorothioate internucleoside linkage, and
 o = a phosphodiester internucleoside linkage.

12. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation:
^mC_{es} A_{eo} ^mC_{es} T_{eo} T_{es} T_{es} ^mC_{es} A_{es} T_{es} A_{es} A_{es} T_{es} G_{es} ^mC_{es} T_{es} G_{es} G_{es} ^mC_e (SEQ ID NO: 21), wherein:

A = an adenine nucleobase,
^mC = a 5-methylcytosine nucleobase,
 G = a guanine nucleobase,
 T = a thymine nucleobase,
 e = a 2'-MOE sugar moiety,
 s = a phosphorothioate internucleoside linkage, and
 o = a phosphodiester internucleoside linkage.

13. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation:
 T_{eo} T_{es} ^mC_{es} A_{es} ^mC_{es} T_{es} T_{es} T_{es} ^mC_{es} A_{es} T_{es} A_{es} A_{es} T_{es} G_{es} ^mC_{es} T_{es} G_{es} G_{eo} ^mC_e (SEQ ID NO: 22), wherein:

A = an adenine nucleobase,
^mC = a 5-methylcytosine nucleobase,
 G = a guanine nucleobase,
 T = a thymine nucleobase,
 e = a 2'-MOE sugar moiety,
 s = a phosphorothioate internucleoside linkage, and
 o = a phosphodiester internucleoside linkage.

14. A population of modified oligonucleotides of any of claims 1-9, or a population of oligomeric compounds of any of claims 10-13, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

15. A pharmaceutical composition comprising the modified oligonucleotide of any of claims 1-9, the oligomeric compound of any of claims 10-13, the population of modified oligonucleotides of claim 14, or the population of oligomeric compounds of claim 14, and a pharmaceutically acceptable diluent.

16. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable diluent is artificial CSF (aCSF) or phosphate-buffered saline (PBS).

17. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists or consists essentially of the modified oligonucleotide or oligomeric compound and aCSF.

18. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists or consists essentially of the modified oligonucleotide or oligomeric compound and PBS.
19. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists or consists essentially of the population of modified oligonucleotides or population of oligomeric compounds and aCSF.
20. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists or consists essentially of the population of modified oligonucleotides or population of oligomeric compounds and PBS.